MedTrace Logo

Therapy Optimisation for the Treatment of Hairy Cell Leukemia

NCT02131753 · Status: RECRUITING · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 210

Last updated 2024-08-22

No results posted yet for this study

Summary

The trial will test the effectiveness and toxicity of subcutaneous treatment with one cycle of cladribine in patients with hairy cell leukemia requiring treatment.

They have to be untreated so far or may be pretreated with alpha-interferon.

Conditions

  • Hairy Cell Leukemia

Interventions

DRUG

Cladribine s.c. injection, HCL treatment

Patients with hairy cell leukemia and the need for treatment are given cladribine 0.14 mg/kg for 5 consecutive days as a s. c bolus injection

Sponsors & Collaborators

  • University of Giessen

    lead OTHER

Principal Investigators

  • Mathias J Rummel, Prof. Dr. · Justus-Liebig-University | University Hospital | Medicinal Clinic IV

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-05-31
Primary Completion
2025-12-31
Completion
2027-12-31

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02131753 on ClinicalTrials.gov